BioLineRx (BLRX) to Release Earnings on Thursday

BioLineRx (NASDAQ:BLRX) is expected to issue its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect BioLineRx to announce earnings of ($0.15) per share and revenue of $0.4280 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 6:46 AM ET.

BioLineRx (NASDAQ:BLRX) last posted its earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.68. The company had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $0.34 million. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.

BioLineRx Price Performance

Shares of BioLineRx stock opened at $2.71 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.58 and a quick ratio of 1.43. BioLineRx has a 1-year low of $2.15 and a 1-year high of $4.56. The business’s fifty day moving average price is $3.05 and its two-hundred day moving average price is $2.86. The company has a market capitalization of $11.84 million, a P/E ratio of -1.41 and a beta of 1.54.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioLineRx in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

About BioLineRx

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.